Search results
Results From The WOW.Com Content Network
In 2015, pulmonary sarcoidosis and interstitial lung disease affected 1.9 million people globally and they resulted in 122,000 deaths. [10] [11] It is most common in Scandinavians, but occurs in all parts of the world. [14] In the United States, risk is greater among black people as opposed to white people. [14]
Löfgren syndrome is a type of acute sarcoidosis, [1] an inflammatory disorder characterized by swollen lymph nodes in the chest, tender red nodules on the shins, fever and arthritis. [2] It is more common in women than men, and is more frequent in those of Scandinavian, Irish, African and Puerto Rican heritage.
Interstitial lung disease affects gas flow in the alveoli The alveoli Micrograph of usual interstitial pneumonia (UIP). UIP is the most common pattern of idiopathic interstitial pneumonia (a type of interstitial lung disease) and usually represents idiopathic pulmonary fibrosis.
The differential diagnosis includes other types of lung disease that cause similar symptoms and show similar abnormalities on chest radiographs. Some of these diseases cause fibrosis, scarring or honeycomb change. The most common considerations include: chronic hypersensitivity pneumonitis; non-specific interstitial pneumonia; sarcoidosis
Conglomerate masses can also develop in sarcoidosis, [5] but usually near the hilae and with surrounding paracicatricial emphysema. The disease arises firstly through the deposition of silica or coal dust (or other dust) within the lung , and then through the body's immunological reactions to the dust.
In people who have lung disease prior to a diagnosis of CVID, the differential diagnosis includes sarcoidosis. Sarcoid is also characterised by granulomatous involvement of the lung and therefore patients being investigated for sarcoid should have serum immunoglobulins measured to exclude CVID. [citation needed]
Differential diagnosis: Sarcoidosis, other interstitial lung diseases, hypersensitivity pneumonitis [4] Treatment: Pulmonary rehabilitation, supplemental oxygen, lung transplantation [1] Medication: Pirfenidone, nintedanib [2] Prognosis: Life expectancy ~ 4 years [1] Frequency: 12 per 100,000 people per year [4]
Restrictive lung diseases are a category of extrapulmonary, pleural, or parenchymal respiratory diseases that restrict lung expansion, [2] resulting in a decreased lung volume, an increased work of breathing, and inadequate ventilation and/or oxygenation. Pulmonary function test demonstrates a decrease in the forced vital capacity.